London. -The World’s first point is to protect humans from Ebola, yesterday said the World Health Organization after the results of a trial in Guinea showed that a vaccine is 100% effective.
Initial results of a study that evaluated the immunization of Merck and NewLink Genetics called VSV-ZEBOV more than 4000 people who had direct contact with a patient diagnosed with Ebola, they showed 100% protection after 10 days .
“We believe the world is about to have an effective vaccine against Ebola,” said the expert on immunizations World Health Organization, Marie Paule Kieny.
The vaccine will help end the worst outbreak of Ebola on record is taken, which killed more than 11 thousand 200 people, including children and adults, in West Africa since its inception in December 2013.
Margaret Chan, Director General of the World Health Organization, said during a press conference that the results of the study, published in the online edition of the journal The Lancet They were “extremely promising development”. In addition, the official added that this “change management current Ebola outbreak and future outbreaks” in other parts of the world.
This and other trials of experimental immunizations were accelerated with a huge international effort. “We knew it was a race against time and the trial had to be implemented under the most challenging circumstances,” said John-Arne Röttingen, chief of infectious disease control at the Norwegian Institute of Public Health and president of the group who led the trial .
ring vaccination. The trial to evaluate the effectiveness and safety of the vaccine began on March 23 in Guinea. a single dose of VSV-ZEBOV was tested using the strategy of “ring vaccination” in which people close to someone diagnosed with Ebola were immunized immediately or within days.
The first vaccination was applied when a new patient was diagnosed. Then, those close to the patient (family, neighbors and friends) dosed immunity immediately.
The research yielded data showing a high rate of protection among vaccinated immediately. Researchers, on July 26, decided not to use more strategy “delayed” involving unethical and unnecessary risk.
Among the contacts vaccinated immediately no further cases of Ebola were recorded, while between those who were immunized days only 16 cases were reported, according to the report of the results published in The Lancet.
The tests will continue and will include children from 13 to 17 years and, possibly, for children under six to 12 years, said the WHO. “Our hope is that the vaccine now will help us to stop this epidemic (in Africa) and prepare for the inevitable future epidemics of Ebola,” said Jeremy Farrar, infectious disease specialist and director of the Wellcome Trust charity.
Doctors Without Borders, which has led the fight against Ebola in West Africa, is asking VSV-ZEBOV be applied in other epicenters of the current outbreak, Liberia and Sierra Leone, because the cut transmission chains protect more people.
Currently, clinical trials of the vaccine, which combines with another fragment Ebola safer to train the immune system virus, they are made only people Guinea. (Agencies)
No comments:
Post a Comment